IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Issues Update on Efforts to Roll Out Alzheimer’s Product Hyalolex

India Globalization Capital (NYSE: IGC) today provided investors and interested parties an update on its efforts to launch its principle product for relieving the anxiety, sleep disorders and brain afflictions associated with Alzheimer’s Disease via medical cannabis dispensaries throughout the United States in the next few months. The company stated that dispensaries in Washington, D.C. and Maryland have been identified as initial distribution sites to launch the product once final inventory is secured. Inventory is expected to be secured early next year. Expansion to additional U.S. states will occur next dependent on product procurement and associated compliance achievement. The Medical Marketing Group, Inc., a provider of outsourced product-detailing, education and outreach services, has been engaged to assist with national dispensary expansion ambitions.

To view the full press release, visit http://nnw.fm/X3Ml8

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information, please visit www.IGCinc.us.